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ARTIFICIAL INTELLIGENCE IN ALZHEIMER’S DISEASE.

by
JESSICA LEE BINDER
B.S., University of New Mexico, 2013
DISSERTATION

Doctor of Philosophy Biomedical Sciences

Abstract
To this day, there is no cure for Alzheimer’s disease (AD) and related dementias
(ADRD). With the daunting rise at an exponential rate of ADRD burden and related
deaths, the necessity to find a new line of attack is vital. Pathological accumulation of
microtubule associated protein tau in neurons is a major neuropathological hallmark of
Alzheimer’s disease (AD) and related tauopathies. Attempts have been made to promote
clearance of pathological tau (p-Tau) from neurons via autophagy. Transcription factor
EB (TFEB) has shown to clear p-Tau from neurons via autophagy. However, sustained
TFEB activation and autophagy can create burden on cellular bioenergetics and can be
deleterious. Here, we engineered previously described two-plasmid systems of Light
Activated Protein (LAP) from bacterial transcription factor – EL222 and Light
Responsive Element (LRE) to encode TFEB. Upon blue-light (465nm) illumination, the
conformation changes in LAP induced LRE-driven expression of TFEB, its nuclear entry,
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TFEB-mediated expression of autophagy-lysosomal genes and clearance of p-Tau from
neuronal cells and AD patient-derived human iPSC-neurons. Turning the blue-light off
reversed the expression of TFEB-target genes and prevented p-Tau clearance. Together,
these results suggest that optically regulated TFEB expression unlocks the potential of
opto-therapeutics to treat AD and other dementias.
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Chapter 1: Introduction Part I: All things Tau
1.1 Overview of Alzheimer’s Disease
In 1907, a German psychiatrist and pathologist, who went by the name Alois Alzheimer,
published his landmark paper about one of his patients. Auguste D, a 51-yr-old patient at
the Frankfurt mental hospital, who displayed severe dementia. It was upon her postmortem autopsy that he described morphologically and histologically to what is now
known as senile plaques and neurofibrillary tangles (Hippius and Neundörfer)1. Over a
hundred years later, the cause to the pathology of Alzheimer’s disease (AD) is still
unknown, and yet it is the 6th leading cause of death in the United States, costing over a
$280 billion every year (source: Alzheimer’s Association).
There are several genetic mutations that cause AD (termed Early-onset Familial
Alzheimer disease (EOFAD)). Studies have shown that single point mutations in APP,
PSEN1, or PSEN2 genes are sufficient to predispose certain individuals develop EOFAD.
However, the prevalence of EOFAD is considerably less than spontaneous/sporadic AD2.
On the other hand, many studies have associated genes wherein certain allelic
polymorphisms can predispose individuals to develop Late-onset Alzheimer’s disease
(LOAD). For example, variants of APOE ɛ4

3

or TREM2

4

are with highest risk of

predisposing LOAD. While the prevalence of sporadic LOAD is more common, these
relative risks are less severe than EOFAD5.
Complex genetics coupled with various co-morbid risk factors including aging,
makes AD and related dementia as one of the complex and perplexing diseases of our
time. Because of this, there is no preventative or therapeutic remedies till date. Recently,
a new theory of omnigenetics6 suggests the risk of certain diseases are not a subset of
1

genetic variants or a collection of a few up/down-regulated genes, but the work of
hundreds to thousands of genetic variants and de/activated genes working in concert. The
more we look at multi-etiologies of AD, finding one gene as the critical/sole player to
disease pathology is profoundly likely be false. The consensus seems the pathology is
derived from various combinations of genes and environment factors.
Currently, two major pathological features in the brain characterize AD: The
aggregation of amyloid beta (Aβ), forming into senile (or amyloid) plaques outside of
cells; and the accumulation of aberrant form of the tau protein called ‘neurofibrillary
tangles’ (NFTs) inside neurons. For decades, the AD research leaned heavily on targeting
extracellular aggregated plaques. Unfortunately, many if not all recent amyloid focused
clinical trials have not been successful

7,8,9

. Thus, the AD field is headed in finding new

drug targets to develop therapeutic intervention against AD and related dementias.

1.2 Neurodegenerative tauopathies
Tauopathies are driven by abnormalities in microtubule-associated protein tau
(MAPT). As the name suggests, its primary function is known to promote nucleation and
stabilization of microtubules (MTs), as well as neuronal growth and function. MAPT or
tau is predominantly found along the axons of neurons and constitutes over 80% of the
neuronal MAPs10. Tau has six different isoforms in adult human brain expressed via
alternative splicing of single mRNA and play unique roles in various neuronal functions.
When post-translational modification of tau occurs, it is thought to be the beginning
stages of neurodegenerative tauopathies11,12,13.
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Phosphorylation of tau is one of the very well-studied post-translational
modifications and known to affect tau’s ability to bind to microtubules and stabilize their
structure13. Studies have suggested that tau phosphorylation is a normal physiological
process to regulate different extent of tau-MT interactions during various stages of central
nervous system (CNS) development11. For example, during early development, when the
neurons are still establishing network connections, it is important to keep the microtubule
in a dynamic stage and it is achieved via keeping the tau hyperphosphorylated on
multiple different residues14. As the CNS develops, phosphorylation of tau on majority of
serines, threonines and tyrosines are significantly reduced to maintain axonal
microtubules in the most stable conditions. However, tau seems to undergo extensive
hyperphosphorylation on almost all of its phospho-sites during disease conditions,
including AD and related tauopathies as well as upon brain trauma following concussions
or traumatic brain injuries15. Strikingly, studies have shown that the tau phosphorylation
during disease condition, occur in a priming manner. That means, for certain
serine/threonine variants in the C-terminal half of protein (For example Ser396/Ser404 –
recognized by the antibody PHF-1) to occur, it is essential to have phosphorylation of
certain N-terminal residues (for example Ser199/Ser202/Thr205 -recognized by the
antibody AT8 and Thr231 – recognized by the antibody AT180) first16,17. Furthermore,
recent studies have suggested that excessive hyperphosphorylation of tau on these
residues could permanently alter tau’s conformation to facilitate tau aggregation,
assembly into paired helical filaments (PHFs) and eventually into neurofibrillary tangles
(NFTs). For example, increasing evidence from Lu’s and other groups have observed a
phenomenon called ‘cistauosis’ where Thr231 hyperphosphorylated tau undergoes from
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‘trans’ conformation into pro-aggregation ‘cis’ conformation that can lead to seeding and
assembly of tau into NFTs18. Therefore, assessing the phosphorylation of tau on AT8,
AT180 and PHF-1 residues are important determinants of early disease events relevant to
tauopathies.
Other examples of neurodegenerative tauopathies include those which are
sporadic: 1) Progressive Supranuclear Palsy (PSP), 2) Corticobasal Degeneration (CBD),
3) Tangle-Predominant Senile Dementia (TPSD), 4) Pick’s disease (PiD) and 5)
Frontotemporal Lobar Dementia – Tau (FTLD-Tau) or familial (Frontotemporal
Dementia and Parkinsonism Linked to Chromosome – 17 tau type (FTDP-17T), which
includes over 30 different intronic and exonic disease-causing mutations in MAPT, such
as a well-studied P301L mutation in the second microtubule binding repeat of tau and
known to cause fronto-temporal dementias19. The mutation P301L lies near the
hexapeptide motifs and increases tau’s tendency to aggregate19. Thus, the accumulation
of the aberrant forms of tau is essentially the basis of neurodegenerative tauopathies.

1.3 Current Tauopathy models
In order to conduct fundamental research, it is imperative to use a disease-relevant
model for better understanding of mechanisms driving pathogenesis. Alternatively,
certain molecular changes can also be assessed in post-mortem brain tissue of
neurodegenerative tauopathy. While the post-mortem tissue has been utilized by many
studies to gain important insights into the transcriptomics, protein analysis and genomewide association studies (GWAS), due to varying post-mortem intervals coupled with
different independent variables and co-morbid conditions, it requires a large group size to
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make any meaningful conclusions. Albeit, these studies illuminated on our understanding
on the hyperphosphorylation of tau, tau oligomerization NFT burden associated with AD,
leading to establishment of Braak staging and post-mortem diagnosis (PMID: 29228201).
Various cell lines (in vitro) and mouse models (in vivo) have also been generated in
efforts to recapitulate the pathology of tauopathies20.
Neuroblastoma cell lines (mouse and human neuroblastoma cells called Neuro 2a
or N2a, and SH-SY5Y, respectively) are commonly used as in vitro models. Our group
and others have designed tauopathy in vitro models that involve SH-SY5Y’s or N2a’s
overexpressing

human

tau

via

P301L

mutation21,

phosphorylation-mimicking

mutations22, cis/trans tau23, or with inflammation-inducible phosphorylation of Tau24.
We have utilized inflammation-induced phosphorylation of tau models by treating murine
N2a or human SHSY5Y cells, expressing human wild-type or mutant tau, with condition
media (CM) derived from lipopolysaccharide (LPS)-primed mouse RAW 264.7
macrophage or BV-2 cells (murine neonatal microglia that were raf/myc-immortalized
25

).

Figure 1.1 | Schematic of inflammation-induced MAPT hyperphosphorylation in neuronal cells.

More recently, induced pluripotent stem cells (iPSCs) have made streamline of
disease models, specifically in neurogenesis or neurodegenerative diseases26,27,28. The
exquisiteness of using iPSCs is that when they are differentiated into the cells of interest,
5

they display the same phenotype characteristics their donor, thus representing a relevant
ex vivo disease model when the iPSCs are obtained from a person with the disease29.
iPSC-based models hold tremendous potential for the study of human development and
disease. iPSC-derived cells are providing a physiologically relevant model for drug
discovery, cell therapy validation, and disease research. Previous studies have utilized
AD patient-derived iPSCs to study various mechanisms of the disease30.
Since 1995, many in vivo mouse models for tauopathies have been
generated31,32,33. These include cDNA-based model where the human tau (MAPT)
transgene with or without disease-relevant mutations (e.g. FTDP-17) are driven by the
promoters specific to neurons34. In addition, there are genomic mouse models where the
human MAPT is driven under the control of endogenous human MAPT promoter 35. The
benefits of using genomic mouse models over cDNA models are that the transgene is not
overexpressed beyond their normal physiological level and therefore can be more
relevant to human disease conditions. Nonetheless, most of these disease animal models
do not exhibit complex disease pathologies but rather a small fraction thereof. More
specifically, it is challenging to recapitulate disease pathology when the initiation of the
disease is still unknown. Furthermore, animal’s epigenetics regulation of human
transgene may become a confounding factor and can make the interpretation difficult.
Our group has investigated in various tauopathy mouse models, for example, a genomic
hTauMaptKO(Duke) model (where human MAPT is driven by the endogenous human MAPT
promoter and therefore expresses all six different isoforms of human tau in the
endogenous mouse Mapt background36). By performing whole genome gene-expression
analysis in the hippocampus, we have uncovered that the hTauMaptKO(Duke) mice show
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altered levels of a novel regulator of taupathy called methyl CpG binding protein 2
(MeCP2) – a neuronal protein which has been shown to play an important role in Rett
Syndome 35(discussed in Appendix A). In addition, we have also utilized a doxycycline
regulatable mouse model of tauopathy, rTg4510, which express human tau carrying
P301L FTDP-17 tau mutation, which can be suppressed by treating mice with
doxycycline37. We have shown that suppression of mutant P301L human tau can reduce
neuroinflammatory responses in the brain by showing reduced expression of several
makers in the IL-1β signaling pathway (discussed in Appendix B). However, AD
mammalian models can only unravel few characteristics of the disease. Altering one or
two genes in an entire system will very unlikely provide a complete picture on the impact
of human transgene overexpression on the disease pathgenesis. Therefore, it is difficult to
corroborate any conclusion from these models. Nevertheless, it is essential and necessary
to investigate these types of models, as the results have revolutionized our understanding
of various diseases. Moreover, with the vast number of research published, assembling
these individual studies and their results together would provide more insight into disease
pathologies. Intergrating our understanding arising from various types of cell/animal
models to gain better insights into the patho-etiology of tauopathies, which will
eventually help us develop new preventive therapies and cures.

1.4 Tauopathy Interventions
Unfortunately, there is no way to prevent or cure AD and related tauopathies at
this time. On the pharmacological level, cholinesterase-inhibitors (ChEIs) 38, N-methyl-daspartate (NMDA) antagonist memantine, or lithium and propentofylline (PPF) have
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been approved by the FDA for treatments to AD. However, all of them provide
symptomatic relief and have only shown to only slightly delay loss of mental abilities in
people who have mild to moderate AD 39. Other studies are suggesting combinations of
drug therapy with exercise may slightly help prolong disease onset 40.
Specific to Aβ and tau, several studies have attempted to target β- and γsecretases (that cleaves amyloid-precursor protein or APP to generate Aβ), kinases (that
hyperphosphorylate tau) or aggregation inhibitors as prevention of Aβ, tau aggregates or
NFTs with little to no success41. Other investigators have explored avenues upstream, i.e.,
the triggers of tau-specific kinase activity42 or downstream phosphatase activity43.
However, the tau kinases and phosphatases are also crucial for other complex pathways,
therefore targeting them has proved to be challenging and therefore, these are unlikely
favorable targets to develop therapy against tauopathies, or it might require a
combinatorial approach in testing multiple targets. Given that more and more studies
failed to meet a successful end-point with the Aβ−targeted therapy and that NFT
pathology seem to better correlate with cognitive decline, the rest of this write-up will
primarily focus on tau/NFT-targetting approaches. Accordingly, some studies are still
targeting certain kinases, such as Cyclin-dependent kinase-5 (CDK5)44, or Glycogen
synthase kinase (GSK-3beta)45. Furthermore, tau aggregation inhibitors have also been
seriously considered as a choice. Rhodanines are small compounds capable of disrupting
the β-sheet structure within the microtubule-binding region of tau, the hexapeptide motif
46

. However, the approach of a single-target approach to treat AD is considerably flawed

as we have yet to identify components that halt AD progression in majority of patient
population with tauopathies.
8

More recently, researchers have been investigating possible clearance enhancing
mechanisms to target pathological tau. An interesting strategy to prevent p-Tau from
becoming pathological is to promote its degradation via autophagy in “at risk” neuronal
populations. As such, there are clinical trials underway to promote clearance of tau and
other aggregated proteins in patients with AD and Parkinson’s disease (NCT02947893,
NCT02281474). Moreover, impairment of autophagic processes has been implicated in
several neurodegenerative disorders47,48,49,50,51,52,53, which further supports autophagy’s
role in clearing p-Tau and maintaining homeostasis as a potential strategy. Previous work
from Dr. Deretic’s group provided compelling evidences that autophagy prevents
spurious

inflammasome/interleukin-1β

(IL-1β)

activation54,55,

which

when

left

uncontrolled, could drive tau pathology and cognitive impairment56. Other studies have
also suggested that promotion of autophagic processing can enhance clearance of p-Tau
and rescue neurotoxicity in a mouse model of tauopathy57. We have demonstrated that
induction of autophagy via chemical or genetic means lead to the clearance of
inflammation-induced p-Tau58 in neuronal cells. Transcription Factor EB (TFEB)
regulates transcription of an entire CLEAR (Coordinated Lysosomal Expression and
Regulation) network, which consists of a consensus site predominately found in the
promoter regions of autophagy-lysosomal genes59,60. Thus, when TFEB localization is
nuclear, it leads to a robust increase in lysosome biogenesis, and results in accelerated
degradation of autophagic substrates61,62. Phosphorylation of Ser211 in TFEB by
mammalian target of rapamycin complex 1 or mechanistic target of rapamycin complex 1
(mTORC1) is one of the key regulators of nuclear localization, as the S211
phosphorylation prevents TFEB from entering into the nucleus63. However, the limitation
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of pro-autophagy studies is their focus on the continual activation of autophagy. While
autophagy is generally thought to promote survival as discussed above, under certain
conditions sustained autophagic-flux can lead to cell death64.
Furthermore, prolonged activation of autophagy proteins (e.g., LC3 and BECN1)
and vacuoles in response to ischemic stroke/reperfusion in vivo, or oxygen-glucose
deprivation in vitro lead to significant cell death65. Interestingly many autophagic
processes do not significantly affect cell health until days after the injury, indicating that
prolonged activation is critical for cell death to occur66,67. Another example, constitutive
activation of the δ2 glutamate receptor was demonstrated to cause Purkinje cell death in
Lurcher mice via activation of autophagy68. Thus, for elderly tauopathy patients with comorbid conditions such as ischemia and vascular dementia, sustained activation of
autophagy could exacerbate cell death rather than reduce it. Therefore, it is crucial to
develop a tunable system to turn-on/turn-off autophagy in neurons with optimum
temporal control.

10

Chapter 2: Rationale, hypothesis, and specific aims
2.1 Rationale The rationale for the proposed research is that the use of light-induced
regulation of autophagy could reduce p-Tau with minimal side effects. Therefore, our
study will validate this novel platform for optogenetic-based strategies to regulate gene
expression and target multiple cellular signaling cascades thought to underlie a variety of
disorders. Regardless of the outcome, the positive impact of these studies will be the
development of a novel and flexible system to rapidly regulate one or more signaling
cascades relevant to neurodegenerative disorders using light-based methods.
2.2 Hypothesis Our central hypothesis is that light-induced expression of a master
regulator of autophagy, Transcription Factor–EB (TFEB), will accelerate the autophagy
process, clear NFTs within neurons, prolong cell survival, and improve cognitive
function.

11

Figure 2.1 | Hypothesis schematic

2.3 Specific Aims The above hypothesis was tested under two specific aims:
Specific Aim 1: Optimization of optogenetic TFEB gene expression system in a neuronal
cell line. 1.1 What are the parameters necessary for optimal light induced gene expression
within neurons? 1.2 Can TFEB target various forms of Tau? 1.3 Does TFEB need to be
modified for optimal induction of autophagsomal/lysosomal transcription factors upon
light stimulation?
Specific Aim 2: Light-Induced TFEB-mediated reduction of hyperphosphorylated and
aggregated p-Tau in cell line models of tauopathy. 2.1 Does light-induced TFEB
expression reduce p-Tau in cellular models of tauopathy? 2.2 Examine the temporal
dynamics and autophagocytic activity in human inducible-pluripotent stem cell-derived
neurons.
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Chapter 3: Optogenetic gene expression systems
3.1 Overview of Optogenetics
In the last fifteen years, researchers have been taking advantage of various
opsins69 and their unique light-sensitivity functions. The unique function of opsins has
transpired into a plethora of light responsive engineered systems70,71,72. More specifically,
the discovery of channelrhodopsin73,74 led to optical control within mammalian neuronal
excitability functions68,75,76,77,78. These genetically engineered channelrhodopsins have
contributed to our understanding of neuronal-basis to various behavioral functions79. To
date, optogenetic technology has been primarily utilized to alter membrane excitability in
neurons using microbial opsins that gate ion channels80. However, an underutilized
application of this technology is that of reversible optical regulation of transgene
expression81. From the original chemical regulation, e.g., the tetracycline-regulated
transcription system82 emerged the use of plant flavoproteins to activate transcription
factors, therefore utilizing control of their dimerization mechanism and DNA binding
sites with light stimulation83. Thus, in contrast to chemical-based transcriptional
regulators that suffer from complex pharmacokinetics and a primarily one-way regulatory
scheme (ON or OFF), optical approaches offer rapid, reversible induction of gene
expression, cell type and/or area specific, and represent an exciting tool for dissecting
pathological signaling pathways.
Most optogenetic transcription regulation systems are responsive to ranges
between green, blue, and red/NIR wavelengths69. Therefore, this ability to switch genes
‘on’ and ‘off’ with high spatial precision has become a valuable tool in many fields of
basic research84,85,86,87,88,89,90,91,92. Despite the origin of optogenetics in the neuroscience
13

field, only recently has the regulation of an endogenous mammalian transcription factor
by light stimulation in neuronal cell lines been shown93. Importantly, from this
dissertation research, another neuronal targeting optogenetic gene expression system is
developed.

3.2 Red Light (Müller et al. “Control of gene expression using a red- and far-red light–
responsive bi-stable toggle switch.”) 94
Our group first tried an optogenetic gene expression system that consists of a red
light (660nm) 2-3 plasmid system95. First, a bicistronic ‘light response element’ (LRE)
plasmid, is driven by a simian virus 40 (SV40) promoter, where a single transcript
encodes for the light responsive PhyB-VP16 protein as well as the DNA binding PIF6TetR

element.

Figure 3.1 (A) Diagram of recombinant DNA vectors that encode for the light-response element (LRE; left) and the
Reporter (right); activation of transcription occurs in response to red (660nm) light, and can be terminated by exposure
to far red (740nm) light. (B-E) HEK293T cells expressing both the LRE+reporter as well as addition of purified PCB.
Cells maintained in the dark, showed little background expression of the mCherry reporter (D-E) compared with the
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mCherry control plasmid (H-I). In contrast, light exposure was unsuccessful for induction of mCherry expression (BC).

Briefly, Arabidopsis thaliana red/far-red light receptor phytochrome B (PhyB) is
linked to the herpes simplex VP16 transactivation domain and a nuclear localization
sequence (NLS), on the same plasmid separated by a polioviral internal ribosome entry
site (IRESPV), codes for the phytochrome-interacting factor 6 (PIF6) fused to a
tetracycline repressor (TetR). The ‘Reporter’ plasmid contains a tetracycline operator
sequence (tetO) motif upstream of a minimal promoter and the reporter gene. Therefore,
the PIF6 fused to the TetR will covalently bind to the tetO. This system is activated
within milliseconds upon exposure to red light (660nm), converting it to its active state
(Pr) where it can interact with phytochrome interacting factors (PIFs). Engineered PIFs
that are covalently linked to DNA- or transcription factor-binding domains can recruit
Polymerase II to activate transcription of transgenes within minutes when bound to the Pr
protein (Fig. 3.1A). This process can be reversed by exposure to far-red light (740nm),
converting the PhyB(NT) to its inactive state (Pfr), and dissociating the PhyB-PIF
complex. Exposure to inactivating 740nm light causes significant reductions in transgenic
mRNA species within hours, and both activation/inactivation can be regulated with light
exposures as short as one minute.
However there was one pitfall to this optogenetic system. PhyB requires the
binding of the chromophore phycocyanobilin (PCB), which is not found in mammalian
cells but can be purified from Spirulina or purchased commercially. Addition of purified
PCB to culture medium is necessary before illumination. This requires significant
optimization between various cell lines, via optimal dose dependence and imbalance of
media characteristics. More so, this does not bode well for future in vivo studies.
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Otherwise, a third plasmid coding for two enzymes that catalyze the biosynthesis of PCB
from heme can be tri-transfected, which stirs-up the debate of multiple transfection
efficiency concerns. To establish feasibility of the optical gene expression system we
used HEK293T cells with a control, constitutively-active mCherry overexpression vector
(Figure 3.1 F-I), or the light-responsive and reporter system with addition of purified
PCB to the media, as shown in Figure 3.1 A. Cells that received the LRE and reporter
were either exposed to 660nm light (~1mW/mm2) for 3h, or maintained in a dark
condition, and then assayed for mCherry expression 24h later. Figure 3.1 B-C shows
paired bright-field and fluorescent images for HEK293T cells that were light-exposed,
and demonstrate little to no mCherry expression equivalent to cells maintained in the
dark (Figure 3.1 D-E). Expression was not comparable to cells that received the
constitutively-active mCherry vector in either light/dark condition (Figure 3.1 F-I). This
system showed great promise for a few reasons. First, it is in the red/far-red spectrum,
which is shown to be less toxic to cells96. Secondly, the short time frame it takes to
initiate gene expression (3 hrs). However, PCB is the most burdensome factor, due to a
third component (plasmid or purified), lowers the efficacy of success rate for light
induced gene expression. This deems the red-light based optogenetic-based gene
expression method is less favorable in comparison to the traditional tetR and tetO system
ith the addition of doxycycline97. Therefore it is important to find an optogenetic gene
expression system with fewer components and involve addition of little to none external
factors.

3.3 Blue Light (Motta-Mena et al. “An optogenetic gene expression system with rapid
activation and deactivation kinetics”.) 98
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We then analyzed an optogenetic gene expression system that consists of a two-plasmid
system reactive to blue light (450nm)98. This light-inducible gene expression system
utilizes an engineered bacterial transcription factor EL222, containing a Light-OxygenVoltage (LOV) 99,99,100,101 protein and N-terminal VP16 transcriptional activation domain.
This system has been shown to induce transcription of target genes with >100 fold
dynamic range and rapid activation (<10 s) and deactivation (<50 s) kinetics. While this
system has been tested in various mammalian cells and zebrafish embryos, its functional
utility in a human disease model system remains untested.
The corresponding DNA binding region to EL222 was previously optimized with
five copies of a specific EL222 DNA-binding region, [Clone 1–20 base pairs (C120)5]94
(Figure 3.2 A). This consensus site acts as a promoter region for the EL222 binding and
drives the expression of any genes inserted downstream of C120 allowing for transient
expression of the transgene due to relatively fast reductions in expression upon cessation
of light exposure (Figure 3.2 A). For furture terminology, pVP-EL222 is referred to as the
‘light activated protein’ or ‘LAP’, and the pC120 is referred to as the ‘light-response
element’ or ‘LRE’).
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A

Figure 3.2 (A) Schematic of previously established gene expression system derived from an EL222
bacterial transcription factor, termed Light-Activated Protein (LAP); activation of transcription occurs in
response to red (450nm) light. (B-E) HEK293T cells expressing both the LAP and LRE-mCherry. Cells
maintained in the dark, showed little background expression of the mCherry reporter (D-E) compared with
the mCherry control plasmid (H-I). In contrast, 12h light exposure was sufficient to induce mCherry
expression to levels similar to the control overexpression plasmid (compare upper left panels with lower
left panels)

First, we successfully recapitulated the previous studies94 of 450nm lightinducible gene expression in HEK293T cells (Figure 3.2). However, upon fluorescenceactivated cell sorting (FACS) analysis, it is evident that the transfection efficiency was
rather low (Figure 3.3). Compared to ~20% of cells expressing mCherry from a
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constitutive promoter, the LRE-mCherry light induction is rather low, showing only ~7%
of cells were expressing mCherry, and ~1% of cells expressing in the Dark.

Figure 3.3 | Transfection efficiency and light induction analysis via FACS. HEK293T cells expressing
both the LAP and LRE-mCherry or LRE-mCherry alone, comparative to pCMV-mCherry control. Cells
maintained in the dark, showed little background expression of the mCherry reporter compared with the
mCherry control plasmid. In contrast, 12h light exposure was sufficient to induce mCherry expression to
about a third comparative to the control overexpression plasmid.

3.4 Successful optogenetic gene expression system in a neuronal cell line.
Next, we verified that co-transfection of Neuro 2a (N2a) cells with both the
pSV40SV40NLS-LAP and the pLRE-Firefire Luciferase reporter (pLRE-FLuc) resulted in
optically-induced expression of the firefly luciferase reporter. Under this more sensitive
assay102, we observed robust luciferase expression and activity driven by the LAP-LRE
interaction in HEK293T cells (Figure 3.4 B). However, luciferase expression and activity
were more than a two-fold lower in N2a’s compared to HEK293T cells (Figure 3.4 B-C).
In an attempt to optimize the LAP-LRE system for gene expression in neurons we
replaced the SV40 promoter with a stronger cytomegalovirus (CMV) promoter103,104. We
also included an additional cMyc nuclear localization signal (1xNLS or

2xNLS)

sequences105,106 (Figure 3.4 A). The addition of the different promoter was sufficient to
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significantly improve luciferase expression upon blue-light illumination compared to
Dark controls in both HEK293T and N2a cells (Figure 3.4 B-C). We also observed a
different degree of luciferase expression with the different promoter and dual NLS
combinations, pCMV-LAP-2xNLS, showing the most robust induction of luciferase
expression in N2a cells (Figure 3.4 B-C). Due to the notable light-induced transgene
expression by pCMV-LAP-2xNLS in both cell lines, we used this LAP construct for all
optical experiments. However, the question still remains can optically-expressed TFEB
reduce pathological tau in neurons?
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Figure 3.4 | Optogenetic gene expression system in neuronal cell line. A. Schematic of our optimized
changes made to the LAP construct for successful neuronal transfection/induction as well as TFEB cloned
into the LRE construct. B-C. Quantitative comparison of various versions of LAP constructs using pLREFirefire Luciferase reporter, (pLRE-FLuc) in HEK293T’s and Neuroblastoma cell line N2a’s, measuring
luciferase activity units (RLU) via radiance levels detected by IVIS (mean + s.e.m, Student’s t test or oneway ANOVA with Tukey multiple comparison test, ****p<0.0005 n=5)
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Chapter 4: Optogenetic TFEB
4.1 TFEB clears multiple forms of pathological tau with equal efficiency in cellular
models of tauopathy.
To test the ability of optically induced transgene expression to clear p-Tau, we chose
TFEB, which is a well-established regulator of autophagy, and previously implicated in
clearing tau via constitutive activation40. As a first step, we decided to confirm whether
TFEB could clear p-Tau and determine whether TFEB can target multiple forms of p-Tau
via autophagic flux in neuronal cells. The MAPT gene in humans encodes six different
isoforms that differ based on inclusion or exclusion of exons 2, 3 and 10107. Exon 10
encodes the second microtubule binding repeat, thereby resulting in tau with either three
(3R) or four (4R) microtubule binding repeats of 31–32 amino acids in the C-terminal
half of tau47. Exons 2 and 3 encode one (1N), two (2N), or zero (0N) amino terminal
inserts of 29 amino acids each in the N-terminal half of the protein47. In normal adult
brain, the relative amounts of 3R tau and 4R tau are approximately equal. However, in
many neurodegenerative tauopathies, the 3R:4R ratio is often altered108. Besides altered
isoform ratios, post-translational modifications such as phosphorylation can also affect
tau’s function and contribute to disease pathogenesis. We tested whether TFEB can clear
following types of p-Tau: (1) 0N3R – non-mutant tau, when over-expressed can lead to
Pick’s

Disease

(PiD)109,

(2)

0N3R

(T231D/S235D)

tau,

which

mimics

hyperphosphorylation on T231/S335 sites and is known to disrupt tau’s interaction with
microtubules110, (3) 0N4R – non-mutant tau, but over-expression can lead to progressive
supranuclear palsy (PSP)111, and (4) 0N4R-P301L mutant tau, which cause FTDP17T112,113. Others and our group have previously shown that TFEB-induced autophagic
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flux degrades p-Tau via beclin-1 dependent autophagy pathway31,32. However, it is
unclear whether TFEB can target and clear various pathological forms of tau. Here we
co-transfected N2a cells with constitutive TFEB expressing vectors and each tau
constructs (0N3R, 0N3R(T231D/S235D), 0N4R, or 0N4R-P301L) individually at a 1:1
TFEB:p-Tau ratio. As revealed by western blot, TFEB expression caused a significant
reduction in all forms of tau in N2a cells with T231D/S235D phosphorylation-mimicking
tau showing the most significant reduction (Figure 4.1 A-B). Together, these results
suggest that TFEB can consistently clear different types of p-Tau in neuronal cells.
Furthermore, since the T231 mutation causes a potent neurotoxic conformation called cisp-Tau (or ‘Cistauosis’, as a result of phosphorylation of tau at T231)114,115,116, TFEB’s
role in significantly reducing T231D/S235D levels supports the therapeutic potential of
targeting TFEB against tauopathies.

Next, we also determined whether or not TFEB with different tags (FLAG versus
GFP) would affect its ability to clear p-Tau via autophagy. Co-expression of
T231D/S235D tau with either pCMV-TFEB3xFLAG or pCMV-TFEB-GFP showed that
GFP tagged TFEB has better efficiency in inducing p-Tau reduction than 3xFLAG tagged
TFEB (Fig. 4.1C-D).
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Figure 4.1 | TFEB differentially targets various forms of pTau.
A-B. Western blot and quantification showing significant reduction in various forms of tau via WT –
0N3R, (0N3R) T231D/S235D, (0N4R) P301L, and WT – 0N4R with the addition of constitutive
overexpression of TFEB activity. Results indicated most forms of tau are equivalently reduced by TFEB,
however (0N3R) T231D/S235D shows highest significance in expression and reduction. Total tau/GAPDH
ratio (mean + s.e.m, Student’s t test, **p<0.01 n=3) C-D. Western blot and quantification showing
significantly reduced (0N3R) T231D/S235D with the addition of various forms of constitutive TFEB
overexpression; pCMV-TFEB3xFLAG, pCMV-TFEB-GFP, pCMV-TFEB(S211A)GFP. Results indicate
pCMV-TFEB(S211A)GFP holds the best yield in total tau reduciton. Total tau/GAPDH ratio (mean +
s.e.m, one-way ANOVA with Tukey multiple comparison test, ***p<0.005 n=4)

4.2 Different variants of TFEB clear pathological tau with equal efficiency in cellular
models of tauopathy.
We observed that GFP-TFEB/3xFLAG-TFEB distribution appeared homogenous
throughout cells, indicating that overall nuclear entry of the TFEB was relatively low.
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Nonethelss, this lower level of TFEB within in the nucleus was sufficient to promote pTau clearance. However, to achieve better nuclear entry of TFEB, we tested S211A
mutation in TFEB, which was previously shown to prevent phosphorylation by
mTORC1117 thereby facilitates TFEB’s nuclear entry. Given that the transcriptional
promotion of genes in the CLEAR network requires nuclear localization of TFEB, we
next assessed the effects of S211 phosphorylation in TFEB in clearing mutant p-Tau. We
observed robust reduction of T231D/S235D mutant p-Tau when they were co-expressed
with TFEB(S211A)-GFP (Figure 4.1 C-D). While the quantification showed that the
reduction in p-Tau by TFEB(S211A)-GFP was comparable to that of TFEB-GFP,
however the level of significance (p<0.01 vs p<0.005 for TFEB-GFP and TFEB(S211A)GFP, respectively) was different To confirm this trend, we next used AMNIS/FACS
automated image-stream analysis. We quantified the percentage of nuclear TFEB+ cells
between WT and S211A (Figure 4.2). TFEB(S211A)-GFP were averaged to be a 92.5%
population of nuclear TFEB+ cells compared to 85.3% in WT TFEB tranfection.
Together, these results suggest that genetically facilitating the nuclear entry of TFEB via
introduction of S211A single point mutation does provide an added advantage in
enhancing the autophagic clearance of T231D/S235D tau.
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Figure 4.2 | Nuclear comparaison of constitutive TFEB(S211A)GFP in a neuronal cell line.
Quantitative immunofluorescence, FACS, AMNIS showing significant increase in TFEB(S211A)-GFP
nuclear localization comparative to WT. in TFEB (WT), 85.3% of nuclear TFEB+ cells, where as with
S211A mutation, this number increased to 92.5%.

4.3 Optogenetically expressed TFEB activates CLEAR network genes in neuronal cells.
To determine the efficiency of optogenetically-driven TFEB (Opto-TFEB) in N2a cells,
we co-transfected N2a cells with either pCMVSV40NLS-LAP or pCMV-LAP-2xNLS and
pLRE-TFEB(S211A)-GFP plasmids.
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Figure 4.3 | Optogenetic TFEB induction optimal timeline in neuronal cell line. Quantitative
immunocytochemistry showing significant increase in TFEB expression in Light control vs Dark,
comparison of various versions of LAP constructs using pLRE-TFEB-3xFlag. Scale bar: 10 µm

First, we assessed the timeline for the optimal light induction, (Figure 4.3), and
concluded 12 hr’s is the optimum timepoint for light-induced gene expression. After the
cells were stimulated 465nm light for 12h, they were fixed and immunostained to detect
the levels of LAP (VP16) and LRE (TFEB(S211A)-GFP). Substitution of the SV40
promoter for a CMV promoter, along with the addition of a second cMyc NLS resulted in
a significant increase of TFEB expression (revealed by the GFP signal) with light
stimulation compared to the ‘Dark’ control (Figure 4.4 A-B). As expected, the VP16
staining was detectable and localized primarily to the nucleus in cells expressing pCMVLAP-2xNLS (Figure 4.4 A).

27

Figure 4.4 | Optogenetic TFEB induction in neuronal cell line and CLEAR activity readout. A-B.
Quantitative immunocytochemistry showing significant increase in TFEB expression in Light control vs
Dark, comparison of various versions of LAP constructs using pLRE-TFEB-(S211A)GFP. Scale bar: 10
µm C-D. Quantitative comparison of various versions of LAP constructs using pCLEAR-Firefly Luciferase
reporter, (pCLEAR-Fluc) in N2a’s measuring luciferase activity units (RLU) via radiance levels detected
by IVIS (mean + s.e.m, Student’s t test or one-way ANOVA with Tukey multiple comparison test,
****p<0.0005 n=4)

As mentioned, many of the target genes activated by TFEB have been identified,
and all carry the consensus CLEAR motif (5’GTCACGTGAC3’) in their promoter
regions25. To determine whether optically-expressed TFEB (or “Opto-TFEB”) is
functionally active, we used a firefly luciferase (Fluc)-based reporter assay to assess the
expression of CLEAR-dependent genes118. The pCLEAR-FLuc plasmid consists of four
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replicates of the CLEAR consensus sequence upstream of the luciferase gene, thus
representing TFEB transcriptional activity. We transiently co-transfected pCLEAR-FLuc
with pLAPs, and pLRE-TFEB(S211A)-GFP in N2a cells and stimulated with blue light
overnight (12h). Then the cells were treated with D-luciferin (1:100), and culture plates
were immediately (3 - 4 mins after addition of substrate) imaged using luminometer to
detect light output from the oxidation of D-luciferin as a measure of luciferase activity.
As expected, the CMV-driven constitutively active TFEB produced the highest levels of
CLEAR-luciferase signal (Figure 4.4 C-D) that was present even in cells maintained in
the Dark control condition. Interestingly, we observed significantly higher levels of
CLEAR-luciferase signal in cells that expressed Opto-TFEB and were light exposed, but
minimal CLEAR-luciferase signal from samples maintained in the Dark (Figure 4.4 CD). Together, our results suggest that Opto-TFEB expression is induced by blue light
exposure and can functionally activate transcription of downstream targets in the CLEAR
network.

4.4 Opto-TFEB reduces pathological tau in neuronal cells
If light-induced Opto-TFEB can bind the CLEAR motif and drive transcriptional
regulation, we hypothesized that it would be sufficient to induce autophagic flux and
reduce levels of misfolded p-Tau. We first overexpressed human tau carrying the 0N3RT231D/S2345D

double

mutation

along

with

pCMV-LAP2xNLS

and

pLRE-

TFEB(S211A)-GFP in N2a cells. Analysis of TFEB(S211A)-GFP and Tau12 through
western blot revealed statistically significant increases in TFEB expression (Figure 4.5 AB) and reduction in the levels of total tau (Tau12) (Figure 4.5 A-C) in light-exposed cells.
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Confirmatory, unbiased quantitative morphometry analysis for Tau12 levels using highcontent, automated Cellomics® microscopy, revealed a significant decrease in the overall
Tau12 intensity in light-exposed Opto-TFEB+ cells compared to Dark controls (Figure
4.5 D-F). Confocal analysis further confirmed that the fluorescence signals for Tau12 and
GFP (from TFEB(S211A)-GFP+ cells) were mutually exclusive and non-overlapping
(Figure 4.5 G). Together, these results demonstrate that light-induced expression of
TFEB is capable of reducing overexpressed phospho-mimicking (T231D/S235D) Tau
levels in neurons.

Figure 4.5 | Optogenetic TFEB induction in neuronal cell line reduces neuronal pathological
mimicking tau. A-C. Western Blot analysis showing overall total protein levels are reduced when OptoTFEB is expressed via light stimulation compared to dark. D- F. Cellomics®-based high-content imaging
analysis of the effects on total Tau levels within Dark and Light controls. Cells were automatically
identified based on nuclear staining (DAPI), then cells were selected for positive nuclear green
fluorescence (TFEB(S211A)GFP) to further analyze for Tau12 (RED) intensity levels within 100 pixel
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radius per cell. Briefly, white lines represent cell boundaries, red lines represent positive cytosolic Tau12,
and yellow lines indicate nuclear TFEB(S211A)GFP-positive cells, then subjected by automated image
analysis. G. Representation of colocalization profile for Tau12 (red) and LRE-TFEB(S211A)GFP (green)
analysis. Quantitative confocal immunocytochemistry using N2a cells overexpressing human 0N3RT231D/S235D tau show lack of colocalization of optogenetically induced TFEB expression with Tau12
positive cells. Quantitative morphometric data (mean + s.e.m, Student’s t test, ****p<0.0001, n=3)

To test the efficacy of this system in human-disease relevant model system, we
test Opto-TFEB in induced pluripotent stem cells (iPSC) line from a patient with sporadic
AD (sAD2.1)119. We first confirmed that iPSC-derived neurons (iPSNs) from the sAD2.1
line display robust p-Tau expression (positive for AT8, AT180, and Tau12; Figure 4.6 AC), similar to previous reports118, compared to iPSNs derived from a healthy control line
(AX0018).
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Figure 4.6 | Characterization of sAD2.1 iPSNs compared to healthy control iPSNs. A. Quantitative
immunocytochemistry showing significant increase of p-Tau (AT8) within betaIII-tubulin (neurons) in
sAD2.1 iPSNs compared to normal control AX0018 iPSNs. B-C. Western blot and quantification showing
significantly increased levels of pMAPT (AT8 and AT180) (mean + s.e.m, one-way anova, ***p<0.0005,
n=3).

It is vital to assess the optimal time of transgene transduction efficiency in iPSNs,
therefore we performed a timeline experiment for constituitive pLenti-CMV-mCherry
virus and concluded that Day 7 is the optimal day to induce with light (Figure 4.7), since
the lenti-viral driven expression of mCherry was highest as this stage.
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Figure 4.7 | Lentiviral transduction of iPSNs timeline. Quantitation of pLenti-CMV-mCherry viral
transduction rate. iPSNs were at day 40 when infected with an MOI of 2.

To assess the efficacy of Opto-TFEB in sAD2.1 cells we created lentiviral OptoTFEB constructs (pGF1-CMV-LAP2xNLS and pGF1-LRE-TFEB(S211A)-GFP) and cotransduced sAD2.1 iPSNs (see methods). Similar to results in N2a cells, light-exposed
iPSNs displayed a significant increase in TFEB-GFP expression and a consequential
decrease in both AT8 and AT180 p-Tau levels compared to Dark controls (Figure 4.8 AB). Lastly, it has been established that the LAP spontaneously gets inactivated in the
Dark, thus turning-off the LRE-mediated gene expression120. Therefore, to assess the
temporal dynamics of Opto-TFEB, we analyzed the light-Dark activity across two days.
On day one, a plate of iPSNs was stimulated with light overnight and an identical plate of
iPSNs was left in the dark. After the first time point of light stimulation, a row of cells
was collected for analysis. The following day, the light was left off and another row of
cells were collected for analysis 24 hrs after the first collection. First, we measured the
mRNA levels of three well-known TFEB targets; PTEN23, CTSF25, and MCOLN125
(Figure 4.8 C). On Day one, we observed a significant increase in TFEB expression with
light and up-regulation of TFEB target genes compared to Dark (Figure 4.8 C). The
mRNA levels of TFEB-target genes reduced back to basal levels after a day of no light.
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Western blot analysis to detect total protein levels revealed p-Tau (AT8 and AT180) was
significantly reduced (Figure 4.8 F). Notably, while the total tau levels were unaltered,
Tau12+ bands showed slightly faster migration (Figure 4.8 E), likely because of the loss
of hyperphosphorylated tau pool due to autophagy in the cell lysate. On day two, levels
of TFEB(S211A)-GFP and TFEB targets were down to Dark levels, however the AT8+
and AT180+ p-Tau levels seem to have gradually raised up, but still lower than their
starting levels (Figure 4.8 E). Taken together, for the first time, these results suggest that
light-induced, optogenetic-based expression of TFEB can reduce p-Tau in a human
disease-relevant iPSN cell culture model of tauopathy.
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Figure 4.8 | Optogenetic TFEB clears pTau in human induced pluripotent stem cells derived into
neurons (iPSNs). A-B. Quantitative immunocytochemistry showing significant increase in TFEB
expression with subsequent lower levels of p-Tau (AT8 and AT180) within betaIII-tubulin (neurons) in
Light control compared to Dark, using viral-particle versions, pGF1-CMV-LAP-2xNLS and pGF1-LRETFEB-(S211A)GFP (Scale bars: 10 µm. Mean + s.e.m, Student’s t test, *p<0.05, n=8). C. Two-day
timeline using RT-qPCR analysis of TFEB gene expression and TFEB targets (PTEN, CTSF, and
MCOLN1). Compared to Dark, each sample was taken 24 hours of subsequent time-point. On Day-1, 12hour light stimulation; Day-2 from same sample, light was off. D-F. Corresponding to RT-qPCR time-point
samples, western blot and quantification showing significantly increased in GFP (TFEB) levels and
congruently reduced pMAPT (AT8 and AT180) with the transduction of viral optogenetic TFEB and
subsequent light stimulation. (mean + s.e.m, one-way anova, ***p<0.0005, n=3-6).

4.5 Summary of results
Here we demonstrate the utility of an optical system to transiently control the expression
of TFEB, which is a master transcriptional regulator of autophagy to reduce the load of
pathological forms of tau in neurons. We had to optimize the promoter and NLS of the
original described system39 in order to promote efficient gene expression not only in
HEK293 cells, but also in N2a and iPSN neuronal models of tauopathy. We also observe
that constitutively active TFEB has the capability of inducing the autophagy-mediated
clearance of multiple forms of p-Tau. In addition to promoting autophagy and lysosome
biogenesis, TFEB has been shown to promote a variety of biological functions including
the inflammatory process61, stress-responsive pathways121, oxidative stress122, and
metabolic regulation123. Therefore, considering TFEB as a potential therapeutic target has
to be a cautious move, as it cannot remain in the nucleus and be constitutively active. Our
study

described

here

is

aimed

towards
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achieving

the

transient

‘on/off’

activation/deactivation mechanism using a novel blue-light inducible TFEB gene
expression system that works well in mouse neuronal cell lines and human AD iPSCs
derived into mature neurons. Using disease-relevant iPSCs will have significant
translational value because of they being derived from human fibroblasts and the disease
phenotype is displayed when diffeentiated into another cell type124,125,126. Accordingly,
the benefits of using sAD2.1 iPSCs is that they are derived from a patient with sporadic
AD and when these iPSCs were differentiated into neurons, they display major hallmarks
of AD, including elevated levels p-Tau phosphorylated at Thr23159, Therefore, using
sAD2.1 avoided tri-plasmid transfection, which often tend to show poor efficiency.
Previous studies have utilized iPSNs to assess the role of autophagy in regulating ADendophenotypes. For example, Reddy et al. generated human forebrain cortical neurons
from iPSCs derived from familial AD patients carrying presenilin-1 (PS-1) mutations
(M146L and A246E) and PS-1 knockdowns in neurons127. Using the identical CLEARluciferase reporter assay as our group did, they found a reduction in CLEAR activity in
AD, but not PS1 knockout, forebrain cortical iPSNs. These results suggest the utility of
CLEAR-luciferase assay in determinging the reduction of autophagy flux in diseaserelevant iPSN models of AD. In another study, exposure of iPSC-derived forebrain
cortical neurons with the amino acid metabolite homocysteine caused reduced autophagic
activity via elevation of mTORC1 activity. Therefore, reduction in TFEB activity was
suggested to be due to hyper-phosphorylation of TFEB by mTORC1128.
Not only have we shown successful light controlled expression of TFEB, but we
also effectively enhanced the autophagy flux via mutation of mTORC1 site - S211A,
which facilitated nuclear entry of TFEB and robust clearance of p-Tau in the human AD
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derived iPSNs. Considering the rise of p-Tau levels one day after light was turned off,
proves a spatio-temporal dynamic with our Opto-TFEB system and we hypothesize when
turning off autophagy, the potential kinases are likely activated again and/or likelihood of
re-accumulation of hyperphosphorylated tau. However, to achieve sustained suppression
of p-Tau, precise titration of light-dosing is necessary. It is also essential to induce OptoTFEB at various time-points during the course of p-Tau pathogenesis to assess the
reversibility of tau pathology, which will have high clinical significance. One of the
potential limitations of inducing transcription factors is likelihood of transcriptional
regulation and compensation129 as well as cellular fatigue. Nonetheless, our study
demonstrates the expression and functional efficacy of neuronal Opto-TFEB in inducing
the expression of CLEAR network genes for the induction of autophagy-lysosomal
pathways and p-Tau reduction.
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Chapter 5: Discussion
5.1 Discussion of Opto-TFEB
When studying a complex disease like AD, it becomes overwhelming to consider all the
patho-etiological factors that could drive the disease and come-up with a plausible
strategy to intervene. For example, in the present study, despite developing an optically
controlled TFEB expression as a tool, this may or may not completely cure AD. This is
because our understanding of all mechanisms of causation is still at its infancy. There is
still a lack of consensus on the primary etiology of AD. With the many failed clinical
trials on eliminating protein aggregates we still are searching for answers. As with any
scientific study, there are some limitations to the work presented in this dissertation. For
one, TFEB is highly regulated. We successfully show that when light stimulates TFEB
expression, when turned off, levels of TFEB target genes are brought back down to
endogenous levels. However, it is important to continue the ‘on’ and ‘off’ switch to assess
optimum Opto-TFEBs capability over a longer time period to achieve successful endpoint of reducing p-Tau. Another potential limitation of the system is its low transfection
and transduction efficiency, which perhaps require a robust gene-delivary strategy to
achieve best possible efficiency.
Another component to consider, Opto-TFEB is that this system is a “transcription
factor” driving another transcription factor.

There is an assumed waste of energy

between these two steps. Elimination of one of the transcription factors would deem more
probable for reoccurring light stimulation. Perhaps engineer TFEB to be light inducible,
or potentially the use of CRISPRa targeting CLEAR network genes (discussed in more
detail later in this chapter).
39

Lastly, Blue 450-465nm has been shown to be somewhat toxic to cells130.
Additionally, this wavelength depth of penetration, through brain tissue, is roughly
around 0.3mm – 0.5mm131. Superlatively far-red provides close to 10-fold deeper (~23mm) penetration to the tissue without the need for invasive insertion of optical fibers.
Additionally, potential design and use of an infrared responsive optogenetics system –
which might sound like “Infrared-TFEB”, could provide even deeper penetration in the
brain tissue, which are the ultimate goal in optogenetics and this would avoid the need of
invasive fiber optic implants.
Overall, our results suggest that Opto-TFEB expression unlocks the potential of
opto-therapeutics to treat AD and other dementias. However, it is too far from becoming
therapeutics as the optogenetic technology is still premature. There are a number of
requirements still necessary for the feasibility and testing in complex cells like neurons
and eventually in vivo is prudent.
5.2 Future Directions
5.2.1 Aging and Neuroinflammation
One of the well-established risk-factors for AD is age. The AD risk increases with
age, so is the weakening of the immune system132, hence the name ‘immunosenescence’.
Immunosenescence is implicated in older adults from decline in adaptive immunity;
results in failure to respond to age-related self-antigens, thus dramatically reduce immune
response

and

affects

longevity133.

However,

the

underlying

mechanisms

of

immunosenescence are unclear and limited134. In addition to decreased sensitivity of B
cell antibody production and T cell responsiveness, increased pro-inflammatory cytokines
and inflammatory responses are altered during aging135. Taken together, these findings
40

suggest that aging causes an increasingly pro-inflammatory state and reduced immunity
to infections, rendering individuals more susceptible to disease such as AD.
As mentioned above, aging is the primary risk factor for AD, and the effect aging
has on the immune system is highly negative136,137. Numerous genome-wide association
studies (GWAS) in patients with dementia have implicated many genes in the immune
system and neuroinflammation are contributing factors for AD and related dementias138.
More specifically, studies suggest a strong correlation between tauopathies and microglia
activity139,140. Microglia and astrocytes are arguably the primary sources of cytokines in
AD. However, there seems to be a debate about whether a pro-inflammatory response to
protein aggregates in the brain potentially providing protective characteristics141 or
exacerbate142,143 the disease in a negative feedback loop. In a previous study, our group
has demonstrated that genetically accelerating microglia-specific neuroinflammation in
the brain accelerated AD-related tangle pathology and cognitive impairment in a manner
dependent upon the activation of IL-1β-p38 mitogen activated protein kinase (p38
MAPK) signaling pathway144. Notably, humanized MAPT transgenic mice deficient of
the microglia-specific chemokine (fractalkine) receptor, CX3CR1, exhibited enhanced
tau phosphorylation and aggregation as well as behavioral impairments that correlated
with increased levels of active p38 MAPK.145 Thus, targeting biological process (e.g.
proteosomal degradation or autophagy) that reduce pathological tau (p-Tau) levels or
blocking neuroinflammation may serve as a potential strategy in treating tauopathies. For
example, chronic administration of rapamycin (inducer of autophagy) significantly
reduced microglial activation, Aβ and p-Tau and improved cognitive function in 3xTg
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mouse model of AD146. Autophagy also has the ability to suppress neuroinflammation by
preventing inflammasome activation.147
It is not clear whether TFEB-mediated autophagy can suppress microglial
inflammation that otherwise can induce MAPT pathology and cognitive impairment.
Thus, it is important to study induction of autophagy as a means to block inflammasome
activation (Figure 5.1; required for IL-1β maturation and neuroinflammation) and can
clear intracellular p-Tau aggregates in microglia and neurons, respectively.

Figure 5.1 | Future Direction Hypothesis schematic
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5.2.2 Linking Opto-TFEB to neuroinflammation
One potential future direction is to examine optically-mediated autophagy
induction can reduce p-MAPT in microglia cell lines and reduce inflammatory responses.
First, activate immortalized murine microglial cell line BV2 cells148, by priming with
LPS137, and transduce with pLenti-CMV-TFEB(S211A)-GFP [overexpression of TFEB]
and assess inflammatory responses (IL-1β, Caspase 1, and TNF-α as well as other
cytokines/chemokines via multiplex cytokine array). Second, transduce BV2 cells or
primary microglia with pLenti-CMV-TFEB(S211A)-GFP or control pLenti-CMV empty
plasmids (as described above) and directly treat them with PHFs purified from human
AD brain (Appendix B). After 24 and 48 h, the media will be collected to measure
cytokine levels via multiplex analysis and the cells will be fixed with 4% PFA for
immunofluorescence analysis to detect phagocytized PHF/MAPT aggregates. In a
separate condition, the cells will be processed for biochemical analysis to detect TFEB
expression and other inflammatory proteins (via western blot analysis) or mRNA levels
(via qRT-PCR). Transiently transfect the
dual pGF1-CMV-LAP-2xNLS and pGF1LRE-mCherry optogenetic plasmid system
with mCherry reporter to test viability and
optimal light stimulation. Finally, to validate
the read-outs from murine microglial cells
models, transduce primary human microglia
(from ScienCell® – we currently have in
Bhaskar lab) or develop microglia-like cells
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Figure 5.2. in vivo lentiviral-mediated gene expression. (A)
Diagram of cortical region targeted for injection. (B) Combined
phase contrast and fluorescent images indicating LV-GFP
expression at 10x (left panel), 20x (middle panel), and 40x (right
panel) magnification. Scale bar 50µm. (C) Intracerebral
administration of LV-Flag-TFEB in mice show specific
expression of Flag (green) in numerous neurons of layers III-V
of the cortex. Scale 50 µm.

from iPSCs149, transduce them with pGF1-CMV-LAP-2xNLS and pGF1-LRE-TFEB(S211A)GFP and co-culture with sAD2.1 and isogenic control iPSNs and assess whether
Opto-TFEB expression in microglia could promote autophagy flux and efficiently clear
p-Tau derived from sAD2.1 neurons to prevent cytokine production/secretion and reduce
p-Tau-induced neuroinflammation.
We predict that Opto-TFEB will result in significantly increased (>10-fold
induction) TFEB expression, and that expression levels will correlate with increased
autophagy flux and reduce LPS or PHF/p-Tau induced inflammatory responses in BV2,
primary microglia and primary microglia+iPSN co-culture systems.

5.2.3 Bringing Opto-TFEB in vivo:
We have successfully delivered pLenti-CMV-GFP into the brains of C57BL/6j
mice via stereotaxic injection. Notably, 10 days post-delivery, several neurons in the
orbito-frontal cortex (OFC) displayed intense GFP expression suggesting successful
incorporation of lenti-derived GFP into neuronal genome and subsequent expression of
GFP (Figure 5.2 A-B). In a separate experiment, we delivered LV-TFEB-FLAG into the
cortex of 2-month-old mice and observed that numerous cortical neurons were Flag
positive (Figure 5.2 C). However, further in vivo testing of Opto-TFEB, which is beyond
the scope of the present study, is necessary in order demonstrate the potential utility of
light-induced autophagy flux in clearning p-Tau in mouse model(s) of tauopathy.
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5.3 Genetic engineering potential for AD
Numerous GWAS studies have identified many risk genes show strong
predisposition to developing AD. For example, amyloidogenic mutations in APP, PSEN1,
or PSEN2, FTD mutations in MAPT, and single-nucleotide polymorphisms (SNPs) in
sporadic AD genes (i.e. APOE ɛ4 or TREM2) all could drive and/or increase the risk of
AD and related dementias. There are just too many contributing factors that constitute
high risk for AD development. Therefore, genetic engineering of fixing single gene/set of
genes will very unlikely be interventional strategy for AD. However, from this
dissertation work it suggests that promoting cell’s own clearance mechanisms and/or
immune systems, via enhancing the autophagy flux or suppressing pro-inflammatory
responses, respectively could open-up future research possibilities for testing AD
therapeutics.
While the gene therapy approach may not be the best strategy to test in all forms
of AD, it could still be tested in prodromal AD cases that are familial, autosomal
dominant and carry single point mutations in APP, PSEN1, PSEN2 and MAPT genes.
Furthermore, gene therapy may unlikely be useful in sporadic AD cases where certain
SNPs increases the risk (unlike autosomal dominant traits). Repairing such SNPs may or
may not provide a cure. Nonethelss, it is important to consider efficient gene delivary
system for the current studies to promote efficient integration of LRE/LAP into the
neuronal genome to promote light responsive induction of autophagy flux and clearance
of p-Tau aggregates in neurons. Historically, the first gene therapy clinical trial, in 1990,
involved ex vivo gene transfer to umbilical cord blood cells or to T lymphocytes of
patients with severe combined immune deficiency (SCID) due to mutations in the
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adenosine deaminase (ADA) gene150,151,152. The concept of gene therapy for genetic
disease usually consists of ex vivo functionality. However, later one of the patients died
from a violent innate immune response to the intravenous delivered adenoviral vector in
1999

153

. However, in 2000, another successful gene therapy was reported. This attempt

used an ex vivo retroviral gene transfer, rather than previous intravenous delivery, of the
γc-chain to CD34+ bone marrow cells to cure patients with X-linked SCID154. However,
half of the patients in this trial developed leukemia155. Unfortunately, retroviral vectors
will integrate indiscriminately into the host genome, mostly in transcriptionally active
genes because of their open/unmethylated formation. Even today, the methodology of
gene therapy delivery is not at its full potential, leaving questions and concerns
unanswered. As the method used in chapter two, lentiviral transductions of transgenes
have shown problematic in gene therapy. Therefore, there is still a despirate need for the
gene therapy research for a successful CNS-directed and neuron-targeted delivery
system.
Currently, nucleases employed for genome editing purposes consist of zinc finger
nucleases (ZFN), or transcription activator-like effector nucleases (TALENs) from
microbial origin. However, in 2015, the discovery of CRISPR/Cas9 (clustered regularly
interspaced short palindromic repeats and CRISPR-associated protein 9, RNA-guided
Cas9 endonuclease) made its iconic entrance to the genetic engineering world. CRISPR
technology has proven faster, higher specificity, straightforward, and a more affordable
way for genome editing, in comparison to traditional ZFN and TALENs approaches.
Furthermore, research groups have engineered systems based on Cas9 providing
extraordinary versatility and capabilities for genome engineering/manipulation156,157,158.
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Currently, there are several clinical trials emerging for gene therapies using
CRISPR/Cas9 technology (source: clinicaltrials.gov). The CRISPR/Cas9 system has also
been adapted to generate technologies called CRISPRi (CRISPR interference)159 and
CRISPRa (CRISPR activation)160. These utilize nuclease-deactivated Cas9 (dCas9) that
cannot generate a double-stranded breaks (DSB) (Figure 1A), but much like optogenetic
gene expression systems, target genomic regions resulting in RNA-directed
transcriptional control. CRISPRa is very similar to our LAP, in that dCas9 is fused to a
transcriptional activation domain, which can be directed to promoter regions by quide
RNA (gRNA). Utilizing CRISPRa to target CLEAR sites found in promoter regions,
would avoid TFEB regulation as mentioned above.
5.4 Overall Conclusions
This dissertation successfully demonstrates an engineered genetic tool that provides
positive spatio-temporal regulation of p-Tau levels in an AD iPSN model.
It does so by first providing a comprehensive outline on the burden of tauopathies and
their pathology. Traditional tauopathy models were briefly examined, followed by the
importance of current and past clinical approaches to the treatment of AD. An attempt to
alleviate AD pathology was suggested by Opto-TFEB as well as potential other cell types
and mechanisms the autophagy could potentially be beneficial. It may be interesting to
see if tunable Opto-TFEB expression system via light would work in other cell types
within the CNS. Conversely, it is also important to determine whether or not such
regulation is applicable to other genes of interest (example, protein phosphatases, which
could dephosphorylate hyperphosphorylated tau). While these questions are very likely
be attempted in future studies, our data strongly suggest that Opto-TFEB efficiently
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expresses in AD iPSNs, up-regulates TFEB target genes, and efficiently facilitates the
clearance of p-Tau. Though it has been a hundred years since AD was first described,
there is still much to be learned about the tauopathy and neuroimmune interface.
Therefore, the field also needs a more diligent way, or “bigger processor”, than our
human minds to comprehend these very complex diseases. Leaning on computational
problem solving will be the way of the future. As it was said by Prof. Ehud Keinan, "All
biological systems, and even entire living organisms, are natural molecular computers.
Every one of us is a biomolecular computer, that is, a machine in which all components
are molecules "talking" to one another in a logical manner. The hardware and software
are complex biological molecules that activate one another to carry out some
predetermined chemical tasks. The input is a molecule that undergoes specific,
programmed changes, following a specific set of rules (software) and the output of this
chemical computation process is another well defined molecule."
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Methods:
Vector construction
All constructs were cloned using NEB HIFI Assembly Kit (NEB # E5520S) with
restriction enzymes and PCR amplification. Briefly, the original episomal plasmids gifted
by Motta-Mena, (pVP-EL222 and pGL4-C120-mCherry) were cloned into different
backbones with subsequent promoters and /or gene of interest; pN1-CMV-TFEB-GFP
(Addgene # 38119). Newly cloned episomal plasmids were then additional cloned into
lentivector backbone, pGF1-NfkB-EF1-Puro (Systemsbio # TR012PA-P). Q5® SiteDirected Mutagenesis Kit was used to make mutations (S142A and S211A) in TFEB
gene (NEB # E0445S). All Tau constructs used; 1) pRC/CMV - 0N3R-tau (human tau
with three microtubule-binding repeats with no N-terminal inserts); 2) 0N4R-tau (human
tau with four microtubule-binding repeats with no N-terminal inserts); 3) 0N4R-P301L
(human tau with four microtubule-binding repeats with P301L FTDP-17T mutation); 4)
0N3R-T231D/S235D. See supplemental Table 1 for all cloned vectors and their
corresponding names.
Cell Lines
HEK293T and Neuro-2a (ATCC # CRL-3216 and #CCL-131, respectively) cells were
maintained at 37°C in 5% CO2 in DMEM supplemented with 10% FBS, 5%
penicillin/streptomycin, and grown in 24-well plates. For transient transfections, cells
were split the day before ~ 1- 4 × 105 cells/well, therefore 70-80% confluence the
following day. Before transfection, media was replaced with phenol red free media,
(FluoroBrite DMEM; ThermoFisher # A1896701). Cells were then transfected with
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Lipofectamine 2000 (Invitrogen) as per company’s protocol. Dilutions of various plasmid
concentrations were as followed for a 24-well plate; pLAP’s – [2000ng/µL], pLRE’s –
[500ng/µL], pCMV-TFEB’s – [500ng/µL], pCMV-hTau’s – [1000ng/µL], pCLEARFLuc – [500ng/µL]. Therefore 1:4 ratio of LRE to LAP.
Induced pluripotent stem cells
sAD2.1; Coriell # GM24666, (iPSCs from Fibroblast NIGMS Human Genetic Cell
Repository Description: ALZHEIMER DISEASE; AD Affected: Yes. Gender: Male. Age:
83 YR (At Sampling). Race: Caucasian.)
Briefly, iPSCs were maintained in mTESR +supplement (StemCell # 85850)
Neuron differentiation followed the StemCells neuronal differentiation kit/protocol;
(StemCell #05835, #05833, #08500, #08510). Later medium was changed to
BrainPhys™ without Phenol Red (StemCell #05791) for optical induction. (Neural
progenitor cells seeded at 1.5x 104 cells/cm2 for maturation)
Light Induction
12hrs post transfection, an in-house blue LED device (465 nm, strip of LEDs glued to
PCB board; Amazon) was placed 8cm or 16cm above the plate. Note, the constraints of
the light source also had to be altered (twice the distance than our cell lines; 16cm) due to
higher sensitivity of iPSNs to the blue-light and the heat it produces, compared to N2a
cell lines. The intensity of the light received by cells was measured to be to 8 W/m2; as
previously reported by42. Verified, using the LI-190 Quantum Sensor and LI-250A light
meter (LI-COR Biosciences). The LED strips were connected to SLBSTORES 3528
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5050 12V DC Mini Remote Controller (Amazon) for variations of on/off patterns to best
match a cycle of 20 s on and 60 s off as recommended per Motta-Mena et al42. The
control plate was kept in a PCB blackout box with breathable air slots, (a shelf in the
incubator, above and away from the light source shelf). For transiently transfected cells,
24hrs post-transfection, samples were collected/fixed for analysis.
Lentivirus production and luciferase assay
Using HEK293T’s, seeded in 100mm plates. Lentiviral Transgenes were cloned into the
pGF1-EF1-Puro backbone. Lentiviral packaging vectors: pMD.2, pPAX2 (Invitrogen cat.
no. K4975-00). Cells were transfected with plasmid mix using CaPO4 precipitation
method, as per protocol Tiscornia et al. 2006 Nat Protocols “Production and purification
of lentiviral vectors”. After 48-hrs interval, the viral supernatant was then filtered through
0.45 µm membranes and mixed overnight with cat#631232 Lenti-X™ Concentrator. The
next day, samples were centrifuged at 1,500 x g for 45 minutes at 4°C. An off-white
pellet is then resuspended in subsequent media, ex: if iPSNs, then neurobasal. Lentiviral
titer was measured using cat#631280 Lenti-X™ GoStix™ Plus.
Lentiviral Transduction on iPSNs – an IFU of 1x10^6/mL were added to the neurons to
make ~MOI = 2. We transduced sAD2.1 neural progenitor cells 24 hours after plating on
poly-ornithine/laminin coated coverslips following StemCell maturation protocol.
Subsequently, two weeks after transduction, (Day 40) iPSNs are subjected to light
stimulation (12 hours) or kept in the dark, samples were then collected/fixed for analysis.
For Firefly luciferase activities, 4XCLEAR-luciferase reporter plasmid #66800,
purchased from addgene. D-Luciferin, Potassium Salt (ThermoFisher # L2916) was
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reconstituted in water and was added (1:100) to each well, 3 - 4 mins after addition of
substrate, 24-well plate samples were analyzed through the IVIS Lumina Series II with
system software.
Western blotting (WB) and immunocytochemistry (ICC)
WB - Cells were lysed by RIPA buffer (Thermo #89900), incubated on ice for 30 mins
then centrifuged at 20,000 × g for 15 min. Cell lysate supernatants were then sonicated
for 20secs at 30%, then subjected to SDS-PAGE usage, transferred to PVDF membranes
and detected using the ECL method (Pierce). Protein levels were quantified using ImageJ
(National Institute of Health). Antibodies included; tau12, GAPDH, FLAG, GFP, TFEB,
AT8, AT180, LC3B, LAMP1.
ICC- Cells were plated on coverslips coated with laminin, once cells were ready for
fixation, they were fixed in 4% PFA, blocked with 0.2%triton and 10% donkey serum,
incubated in primary overnight in 4oC (5% DS), secondaries were incubated for 1hr at
RT. Incubated in DAPI for 10 mins, and mounted to slides using fluoromount(CAT#).
Immunofluorescence confocal microscopy was carried out using Zeiss LSM 510 Meta
microscope. Histo and profile analysis was performed using ZEISS ZEN imaging
Software.
Gene expression analysis
RNA from cells was extracted using the TriZOL reagent as described by the
manufacturer (Thermo Fisher Scientific). Total RNA (20 ng/µL) was converted to cDNA
using the High Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific) and
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amplified using specific TaqMan assays (catalog # 4331182; Thermo Fisher Scientific).
GAPDH (catalog # 4352339E, Thermo Fisher Scientific) was used as a housekeeping
gene for normalization. qRT-PCR assays were run on the StepOnePlus® Real-Time PCR
System (Thermo Fisher Scientific) and the statistical analyses were performed using
Prism.
Cellomics®-based high-content imaging analysis
Cells were plated in 96 well plates transiently transfected with pCMV-T231D/S235D
(phosopho-mimicking tau), pCMV-LAP2xNLS, and pLRE-TFEB(S211A)-GFP. Twentyfour hours later, cells were incubated with conditioned medium from BV2’s, as
previously described, then subsequently induced with light (470nm) for 12 hours. Cells
were fixed in 4% PFA, blocked with 0.2%triton and 10% donkey serum, incubated in
primary for one hour at RT (5% DS), secondary was incubated for 1hr at RT. Incubated
in DAPI for 10 mins and analyzed through cellomics machine.
Statistics
Unless otherwise indicated, comparisons between the two groups were done via unpaired
t test; comparisons between multiple treatment groups were done via one-way or twoway analysis of variance (ANOVA) with indicated multiple comparisons post-hoc tests.
All statistical analyses were performed using GraphPad Prism®.
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Table 1: Plasmid list

Plasmids used:
Motta-Mena et al

pGL4-SV40-VP-EL222

Motta-Mena et al
Motta-Mena et al
Addgene #38119
Binder et al.

pC120-MCH
pC120-FLuc
pN1-CMV-TFEB-GFP
pN1-CMV-TFEB(S211A)-GFP

Light
response
element

pN1-LRE-TFEB3xFLAG WT

Bacteria Transcription Factor, EL222,
LOV domain.
mCherry reporter
Firefly Luciferase reporter
Constitutive TFEB- GFP reporter
Constitutive
TFEB
with
(S211A)
mutation- GFP reporter
LRE-Flag reporter (data not shown)

pN1-LRE-TFEB(S142A)3xFLAG
pN1-LRE-TFEB-GFP WT
pN1-LRE-TFEB(S211A)-GFP
pN1-CMV-EL222

LRE-Flag reporter (data not shown)
LRE-GFP reporter (data not shown)
LRE-GFP reporter
LAP, CMV promoter, Sv40 NLS N term

pN1-CMV-EL222-2xNLS
pGF1-CMV-EL222-2xNLS

LAP, CMV promoter, Sv40-NLS, and
cMyc NLS
Lenti-LAP

pGF1-LRE-TFEB(S211A)-GFP

Lenti-LRE-TFEB-GFP reporter

Light activated
protein

Lentiviral
constructs

Table 2 : Antibodies
Antibodies used in western blotting (WB) or immunohistochemistry (IHC) are listed
below.
Antibody

Species

Company and Catalog #

VP16

Rabbit

AT180

Mouse

Thermo Scientific, MN1040

AT8

Mouse

Thermo Scientific, MN1020

GAPDH

Mouse

Millipore,
CB1001-500UG
Tau12

Mouse

Abcam,
MAB2241
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ab74137

Millipore,

Abbreviations Used

AD

Alzheimer’s disease

ADRD

Alzheimer’s disease and related dementias

Aβ

amyloid beta

BV2’s

murine neonatal microglia cell line

CBD

Corticobasal Degeneratio

CDK5

Cyclin-dependent kinase-5

ChEIs

cholinesterase-inhibitors

CLEAR

Coordinated Lysosomal Expression and Regulation

CM

condition media

CMV

cytomegalovirus

CNS

central nervous system

CRISPR/Cas9

clustered regularly interspaced short palindromic repeats and
CRISPR-associated protein 9, RNA-guided Cas9 endonuclease

EOFAD

Early-onset Familial Alzheimer disease

FACS

fluorescence-activated cell sorting

FTDP-17T

Frontotemporal Dementia and Parkinsonism Linked to
Chromosome – 17 tau type

FTLD-Tau

Frontotemporal Lobar Dementia – Tau

GSK-3beta

Glycogen synthase kinase

GWAS

genome-wide association study

IL-1b

interleukin-1b

iPSCs

induced pluripotent stem cells

iPSNs

induced pluripotent stem cells derived neurons
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IRESPV

polioviral internal ribosome entry site

LAP

Light Activated Protein

LOAD

Late-onset Alzheimer’s disease

LOV

Light-Oxygen-Voltage

LPS

lipopolysaccharide

LRE

Light Responsive Element

MAPT

microtubule-associated protein tau

MeCP2

methyl CpG binding protein 2

MT

microtubules

mTORC1

mechanistic target of rapamycin complex 1

N2a’s

mouse neuroblastoma cell line

NFTs

neurofibrillary tangles

NLS

nuclear localization sequence

NMDA

N-methyl-d-aspartate

Opto-TFEB

optogenetically-driven TFEB

p-Tau

pathological tau

PCB

phycocyanobilin

PHFs

paired helical filaments

PhyB

phytochrome B

PiD

Pick’s Disease

PIF6

phytochrome-interacting factor 6

PPF

propentofylline

PSP

Progressive Supranuclear Palsy

qRT-PCR

quantitative real time PCR

S/Ser

Serine

SH-SY5Y’s

human neuroblastoma cell line
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SV40

simian virus 40

T/ Thr

Threonine

TFEB

Transcription factor EB

TPSD

Tangle-Predominant Senile Dementia
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Appendix A. Published article in Frontiers in molecular neuroscience co-authored
by Jessica Binder
Whole genome expression analysis in a mouse model of tauopathy identifies MECP2
as a possible regulator of tau pathology
Nicole Maphis1, Shanya Jiang1, Jessica Binder1, Carrie Wright2, Banu Gopalan3, Bruce
T. Lamb4 and Kiran Bhaskar1*
Abstract
Increasing evidence suggests that hyperphosphorylation and aggregation of microtubuleassociated protein tau (MAPT or tau) correlates with the development of cognitive
impairment in Alzheimer’s disease (AD) and related tauopathies. While numerous
attempts have been made to model AD-relevant tau pathology in various animal models,
there has been very limited success for these models to fully recapitulate the progression
of disease as seen in human tauopathies. Here, we performed whole genome gene
expression in a genomic mouse model of tauopathy that expressed human MAPT gene
under the control of endogenous human MAPT promoter and also were complete
knockout for endogenous mouse tau (referred to as ‘hTauMaptKO(Duke)’ mice). First, whole
genome expression analysis revealed 64 genes, which were differentially expressed (32
upregulated and 32 down-regulated) in the hippocampus of 6-month old hTauMaptKO(Duke)
mice compared to age-matched non-transgenic controls. Genes relevant to neuronal
function or neurological disease include upregulated genes: PKC-alpha (Prkca), MECP2
(Mecp2), STRN4 (Strn4), SLC40a1 (Slc40a1), POLD2 (Pold2), PCSK2 (Pcsk2), and
down-regulated genes: KRT12 (Krt12), LASS1 (Cers1), PLAT (Plat) and NRXN1
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(Nrxn1). Second, network analysis suggested anatomical structure development, cellular
metabolic process, cell death, signal transduction and stress response were significantly
altered biological processes in the hTauMaptKO(Duke) mice as compared to age-matched nontransgenic controls. Further characterization of a sub-group of significantly altered genes
revealed elevated phosphorylation of MECP2 (methyl-CpG-binding protein-2), which
binds to methylated CpGs and associates with chromatin, in hTauMaptKO(Duke) mice
compared to age-matched controls. Third, phoshpho-MECP2 was elevated in autopsy
brain samples from human AD compared to healthy controls. Finally, siRNA-mediated
knockdown of MECP2 in human tau expressing N2a cells resulted in a significant
decrease in total and phosphorylated tau. Together, these results suggest that MECP2 is a
potential novel regulator of tau pathology relevant to AD and tauopathies.
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Figure 5. MECP2 regulates tau pathology in vitro. N2a cells transiently transfected with
human tau 0N3R isoform (‘+Tau’) or a control plasmid (‘-Tau’) were nucleofected with
siRNA (scramble siRNA (siScr) or MECP2 siRNA). After 24 h of siRNA nucleofection,
the cells were harvested and probed for AT180, PHF-1, Tau5, Tau12 and total MECP2.
(A-B) Note that siMECP2 significantly reduced levels of MECP2 in both ‘-Tau’ and
‘+Tau’ N2a cells (*p<0.01 unpaired t test; n=3 replicates; mean + SEM). (C-D) siMECP2
treatment also significantly (*p<0.01 unpaired t test; n=3 replicates; mean + SEM)
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reduced the levels of both total tau (Tau5/GAPDH) and human tau (Tau12/GAPDH)
ratios in the ‘+Tau’ N2a cells compared to scramble siRNA treated conditions. (E-H)
siMECP2 knockdown resulted in statistically significant (*p<0.01 unpaired t test; n=3
replicates; mean + SEM) increase and decrease in AT180/Tau5 and PHF1/Tau5 ratios,
respectively. Note that the ratio for β-actin/GAPDH was not altered either in ‘-Tau’/
‘+Tau’ conditions or with/without siMECP2 conditions.
Appendix A examines the importance of deep characterization within each
tauopathy models. We explicitly used a hTauMaptKO(Duke) in which we identify novel
gene(s) that differentially regulate the expression of human MAPT. More over, we found
significant upregulation of the MECP2 (Mecp2) as well as phosphorylation of MECP2
(methyl-CpG-binding protein-2), which binds to methylated CpGs and associates with
chromatin.
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Appendix B: Submitted article to Neuron co-authored by Jessica Binder

Proteopathic Tau Primes and Activates Interleukin-1ß(Il-1ß) via MyD88- and
NLRP3-ASC-Inflammasome Dependent Pathways
Shanya Jiang1, Nicole Maphis1, Jessica Binder1, Devon Chisholm1, Lea Weston1, Walter
Duran1, Crina Floruta3, Amber Zimmerman3, Stephen Jett4, Eileen Bigio5, Changiz
Geula5, Nikolaos Mellios3, Jason Weick3, Eicke Latz6,7, Michael T. Heneka6,7,8 , and
Kiran Bhaskar1,2*

Abstract
Tauopathies are a group of neurodegenerative diseases characterized by the aggregation
of tau protein as neurofibrillary tangles (NFTs) within the brain, where microglia also
show activated phenotype(1). Interleukin-1β (IL-1β) is a potent pro-inflammatory
cytokine known to play an important role in the pathophysiology of various
tauopathies(2-7) including Alzheimer’s disease (AD)(8-11). Microglial activation is
associated with increased IL-1β in AD(6, 12). Polymorphisms in the IL1B show
significant risk for AD(13-16). However, it is not clear how pathologically modified tau
(pTau) uniquely contributes to neuroinflammation in non-AD tauopathies. Here we show
that elevated pTau strongly correlates with increased levels of both active IL-1β and
apoptosis-associated speck-like protein containing a CARD (ASC) in human frontotemporal lobar degeneration – tau type (FTLD-Tau) autopsied brains. Suppression of
human tau expression, via doxycycline, reduced both priming and activation of
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inflammasome markers (ASC and NLR family pyrin domain 3 or NLRP3) in rTg4510
mouse model of tauopathy. Microglial cells treated with pTau containing neuronal
conditioned media or purified exosomes, led to microglial uptake of pTau, increased
expression and/or activation of ASC, NLRP3 and IL-1β. Purified NFTs from either
human FTLD-Tau or rTg4510 mouse brains activated IL-1β in microglia, which was
dependent upon ASC. Genetic deficiency of ASC within microglia reduced tau
pathology, blocked IL-1β activation, and improved memory in hTau mouse model of
FTLD-Tau. The RNA-sequencing analysis of human primary microglia activated by
human NFTs suggested that, surprisingly, pTau also induced IL-1β expression via the
upregulation of NF-kB pathway. Finally, pTau-driven NF-kB activation and IL-1β
maturation were microglial MyD88-dependent. These results demonstrate that pTau
could prime microglial NF-kB, trigger inflammasome activation and neuroinflammation
in non-AD tauopathies, suggesting that the MyD88/ASC/inflammasome network could
be a potential therapeutic target against FTLD-Tau.
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Figure 2 | Microglial cells take up pathological tau secreted from neuronal cells and
lead to expression and activation of inflammasome-related genes. A-B. LPS-primed
(1µg/ml LPS for 6h) BV2 cells show internalization of human tau when incubated with
conditioned media (CM) from phosphorylation-mimicking tau (0N3R-T231D/S235D)
transfected Neuro 2a (N2a) cells for 24 h prior compared to CM from vector-transfected
(“Mock”) or wild type tau (0N3R-WT) transfected N2a cells (Tau12- red). Scale 20mm
C-D. Western blot and quantification of BV2 cell lysates shows significant uptake of
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human tau (Tau12/GAPDH ratio) and increased protein levels of ASC, pro- and
cleaved(c)-IL-1b, and NLRP3 in BV2 cells treated with CM from WT (0N3R) and/or
(0N3R-T231D/S235D)-expressing N2a cells. E. Quantitative real time PCR analysis of
unprimed BV2 cells shows significantly elevated the expression of mRNA for ASC
(Pycard) mRNA, but not NLRP3/IL-1b, when treated with CM from WT (0N3R) and/or
(0N3R-T231D/S235D) expressing N2a cells. F-H. Immortalized mouse macrophages
expressing ASC-mCerulean or murine primary microglia show significant increase in the
number of intracellular (white arrows) or extracellular (white arrowheads) ASC-specks
when treated with CM from N2a cells expressing 0N3R-T231D/S235D tau compared to
WT tau or Mock. Scale 10mm. Data displayed as mean + SEM, one-way ANOVA with
Tukey multiple comparison test, *p<0.05, **p<0.01, ***p<0.005, n=6 (C, D, E, G, J and
K).
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Figure S4: Characterization of tau in exosomes purified from N2a. (related to Figure
2). A-B. Purified exosomes from N2a CM show vesicles ranging from 50-200nm in
diameter with distinct lipid bilayer and were positive for exosome marker Alix (10 nm
conjugated gold particle (in B) detected via immune-electron microscopy or IEM). These
exosomes were also positive for Tau12 (arrows showing 5 nm gold particles). Scale 100
nm. C-F. Western blot analysis with quantification shows presence of human tau
(Tau12+) in lysates and exosomes of N2a cells transfected with 0N3R-WT or 0N3RT231D/S235D tau. Ratio of Tau12/GAPDH and Tau12/CD81 (CD81 is an exosome
marker) show significantly elevated human tau in both lysates and exosomes compared to
mock (vector only) transfected lysate/exosomes. Data shown are mean + s.e.m, one-way
ANOVA with Tukey multiple comparison test, *p<0.05, n=4 (D); n=3 (F); unpaired
Students t test).
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Appendix B takes a deeper look into connections between tauopathy and
neuroinflammation. In particular, our group has previously shown that microglial
activation is associated with increased IL-1β, which leads to increased p38 MAPK, and in
turn intensifies pTau. However it is not clear if pTau stimulates and uniquely contributes
to neuroinflammation, or vise versa. Thus this article takes a multi-angle approach to
show that neuron-derived pathological tau activates ASC/NLRP3 inflammasomes and IL1β in microglia and leads to brain inflammation relevant to tauopathies.
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